ciprofloxacin has been researched along with Acute Lymphoid Leukemia in 16 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoroquinolones reduce occurrence of fever in adult cancer patients who develop neutropenia, but there has been no randomized controlled trial in children, and there are only a few studies considering resistance in intestinal floral after ciprofloxacin has been used." | 9.17 | Ciprofloxacin reduces occurrence of fever in children with acute leukemia who develop neutropenia during chemotherapy. ( Chelae, S; Khwanna, T; Laoprasopwattana, K; Sujjanunt, T; Suwankeeree, P; Tunyapanit, W, 2013) |
| "The purpose of this study was to identify risk factors and improve preventive strategies for febrile neutropenia (FEN) in children with leukemia who were receiving ciprofloxacin prophylaxis." | 8.31 | Identifying Risk Factors and Improving Preventive Strategies for Febrile Neutropenia in Children with Leukemia Receiving Ciprofloxacin Prophylaxis ( Alıcı, N; Kaya, Z; Kırkız, S; Koçak, Ü, 2023) |
| "To report the first case of ciprofloxacin-associated hemolytic-uremic syndrome (HUS)." | 7.71 | Ciprofloxacin-associated hemolytic-uremic syndrome. ( Allan, DS; Barr, RM; Chin-Yee, IH; Clark, WF; Thompson, CM, 2002) |
| "Fluoroquinolones reduce occurrence of fever in adult cancer patients who develop neutropenia, but there has been no randomized controlled trial in children, and there are only a few studies considering resistance in intestinal floral after ciprofloxacin has been used." | 5.17 | Ciprofloxacin reduces occurrence of fever in children with acute leukemia who develop neutropenia during chemotherapy. ( Chelae, S; Khwanna, T; Laoprasopwattana, K; Sujjanunt, T; Suwankeeree, P; Tunyapanit, W, 2013) |
| "Compared to historical controls, patients in this study receiving prophylactic ciprofloxacin had a reduced rate and duration of hospitalization and incidence of Gram-negative bacteremia." | 5.11 | A pilot study of prophylactic ciprofloxacin during delayed intensification in children with acute lymphoblastic leukemia. ( Abbas, AA; Chedid, FD; Felimban, SK; Fryer, CJ; Khattab, TM; Yousef, AA, 2004) |
| "The purpose of this study was to identify risk factors and improve preventive strategies for febrile neutropenia (FEN) in children with leukemia who were receiving ciprofloxacin prophylaxis." | 4.31 | Identifying Risk Factors and Improving Preventive Strategies for Febrile Neutropenia in Children with Leukemia Receiving Ciprofloxacin Prophylaxis ( Alıcı, N; Kaya, Z; Kırkız, S; Koçak, Ü, 2023) |
| "To report the first case of ciprofloxacin-associated hemolytic-uremic syndrome (HUS)." | 3.71 | Ciprofloxacin-associated hemolytic-uremic syndrome. ( Allan, DS; Barr, RM; Chin-Yee, IH; Clark, WF; Thompson, CM, 2002) |
| "Ciprofloxacin AUC24 was 16." | 1.56 | Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients. ( Bierings, MB; de Haas, V; Kaspers, GJL; Mathôt, RAA; Pieters, R; Sassen, SDT; Te Loo, DMWW; Tissing, WJE; van den Bos, C; van der Sluis, IM; van Westreenen, M; Zwaan, CM, 2020) |
| "Ciprofloxacin therapy was initiated and renal function was restored within 2 days." | 1.33 | Pseudomonas aeruginosa infection: an uncommon cause of post-renal obstruction following induction therapy for acute lymphoblastic leukemia. ( Burghardt, KM; Feber, J; Filler, G; Halton, J; Leonard, M, 2006) |
| "In ciprofloxacin-treated patients the flora were almost completely ciprofloxacin-resistant, whereas in the control groups resistant flora were detected only occasionally." | 1.28 | Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. ( Huovinen, P; Kotilainen, P; Nikoskelainen, J, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kaya, Z | 1 |
| Alıcı, N | 1 |
| Kırkız, S | 1 |
| Koçak, Ü | 1 |
| Sassen, SDT | 1 |
| Mathôt, RAA | 1 |
| Pieters, R | 1 |
| de Haas, V | 1 |
| Kaspers, GJL | 1 |
| van den Bos, C | 1 |
| Tissing, WJE | 1 |
| Te Loo, DMWW | 1 |
| Bierings, MB | 1 |
| van Westreenen, M | 1 |
| van der Sluis, IM | 1 |
| Zwaan, CM | 1 |
| Castagnola, E | 1 |
| Moroni, C | 1 |
| Bandettini, R | 1 |
| Caprino, D | 1 |
| Haupt, R | 1 |
| Fatima, A | 1 |
| Afridi, FI | 1 |
| Qureshi, A | 1 |
| Farooqi, BJ | 1 |
| Hussain, A | 1 |
| Yeh, TC | 1 |
| Liu, HC | 1 |
| Hou, JY | 1 |
| Chen, KH | 1 |
| Huang, TH | 1 |
| Chang, CY | 1 |
| Liang, DC | 1 |
| Laoprasopwattana, K | 1 |
| Khwanna, T | 1 |
| Suwankeeree, P | 1 |
| Sujjanunt, T | 1 |
| Tunyapanit, W | 1 |
| Chelae, S | 1 |
| Yousef, AA | 1 |
| Fryer, CJ | 1 |
| Chedid, FD | 1 |
| Abbas, AA | 1 |
| Felimban, SK | 1 |
| Khattab, TM | 1 |
| Burghardt, KM | 1 |
| Leonard, M | 1 |
| Feber, J | 1 |
| Halton, J | 1 |
| Filler, G | 1 |
| Rosolen, A | 1 |
| Drigo, P | 1 |
| Zanesco, L | 1 |
| Horowitz, HW | 1 |
| Holmgren, D | 1 |
| Seiter, K | 1 |
| Carlens, S | 1 |
| Ringdén, O | 1 |
| Aschan, J | 1 |
| Hägglund, H | 1 |
| Ljungman, P | 1 |
| Mattsson, J | 1 |
| Remberger, M | 1 |
| Allan, DS | 1 |
| Thompson, CM | 1 |
| Barr, RM | 1 |
| Clark, WF | 1 |
| Chin-Yee, IH | 1 |
| Donnelly, JP | 2 |
| Maschmeyer, G | 1 |
| Daenen, S | 1 |
| Arning, M | 1 |
| Wolf, HH | 1 |
| Aul, C | 1 |
| Heyll, A | 1 |
| Scharf, RE | 1 |
| Scheider, W | 1 |
| Kotilainen, P | 1 |
| Nikoskelainen, J | 1 |
| Huovinen, P | 1 |
| Weers-Pothoff, G | 1 |
| Novakova, IR | 1 |
| Muytjens, HL | 1 |
5 trials available for ciprofloxacin and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Ciprofloxacin reduces occurrence of fever in children with acute leukemia who develop neutropenia during chemotherapy.
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agen | 2013 |
A pilot study of prophylactic ciprofloxacin during delayed intensification in children with acute lymphoblastic leukemia.
Topics: Adolescent; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremia; Child; Child, Preschool; Cipr | 2004 |
Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciproflo | 1996 |
Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemia-ciprofloxacin versus co-trimoxazole plus colistin. The EORTC-Gnotobiotic Project Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Agranulocytosis; Ciprofloxacin; Colistin; Drug Therap | 1992 |
Infection prophylaxis in neutropenic patients with acute leukaemia--a randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin.
Topics: Bacterial Infections; Ciprofloxacin; Colistin; Humans; Neutropenia; Ofloxacin; Precursor Cell Lympho | 1990 |
11 other studies available for ciprofloxacin and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Identifying Risk Factors and Improving Preventive Strategies for Febrile Neutropenia in Children with Leukemia Receiving Ciprofloxacin Prophylaxis
Topics: Child; Ciprofloxacin; Febrile Neutropenia; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphobl | 2023 |
Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients.
Topics: Anti-Bacterial Agents; Area Under Curve; Child; Ciprofloxacin; Drug Resistance, Bacterial; Humans; M | 2020 |
Ciprofloxacin prophylaxis in children with acute leukemia in an era of increasing antibiotic resistance.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Ciprofloxacin; Female; Fever; Humans; Male; Neutropeni | 2013 |
Bacteremia due to Aeromonas hydrophila in acute lymphoblastic leukemia.
Topics: Acute Disease; Aeromonas hydrophila; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Female; Fever | 2013 |
Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.
Topics: Adolescent; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Agents; Child; Child, Preschoo | 2014 |
Pseudomonas aeruginosa infection: an uncommon cause of post-renal obstruction following induction therapy for acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anuria; Ciprofloxacin; Humans; Hypertension; Infant; | 2006 |
Acute hemiparesis associated with ciprofloxacin.
Topics: Acute Disease; Adolescent; Ciprofloxacin; Cranial Nerve Diseases; Female; Hemiplegia; Humans; Precur | 1994 |
Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
Topics: Adult; Anti-Infective Agents; Bone Marrow Transplantation; Ciprofloxacin; Cyclophosphamide; Disease- | 1998 |
Ciprofloxacin-associated hemolytic-uremic syndrome.
Topics: Anti-Infective Agents; Ciprofloxacin; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Precurso | 2002 |
Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin.
Topics: Aged; Ciprofloxacin; Coagulase; Drug Resistance, Microbial; Female; Humans; Immune Tolerance; Leukem | 1990 |
Bacteraemia caused by Stomatococcus mucilaginosus in a granulocytopenic patient with acute lymphocytic leukaemia.
Topics: Adult; Agranulocytosis; Amsacrine; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Proto | 1989 |